37
Participants
Start Date
February 27, 2021
Primary Completion Date
December 15, 2021
Study Completion Date
December 27, 2021
Dolutegravir (DTG)
Administered orally
Isoniazid (INH)
Administered orally
Rifapentine (RPT)
Administered orally
Antiretroviral Therapy (ART)
Participants remained on DTG-based ARV treatment with 2 NRTIs (excluding TAF) during the study. NRTIs were not provided by the study. Arm 1 participants took non-study supply of DTG for morning doses, and study-supplied DTG for evening doses. For Arm 2 participants, DTG was to have come from non-study ARV supply.
Pyridoxine (Vitamin B6)
Participants received 25 or 50 mg of pyridoxine (vitamin B6) with each dose of INH, based on the current local, national, or international dosing guidelines. Pyridoxine was not provided by the study.
University of Cape Town Lung Institute (UCTLI) CRS, Cape Town
South African Tuberculosis Vaccine Initiative (SATVI) CRS, Cape Town
Thai Red Cross AIDS Research Centre (TRC-ARC) CRS, Pathum Wan
Houston AIDS Research Team CRS, Houston
University of California HIV/AIDS CRS, San Francisco
Gaborone CRS, Gaborone
Malawi CRS, Lilongwe
Milton Park CRS, Milton Park
GHESKIO Institute of Infectious Diseases and Reproductive Health (GHESKIO - IMIS) CRS, Port-au-Prince
Les Centres GHESKIO Clinical Research Site (GHESKIO-INLR) CRS, Port-au-Prince
Collaborators (1)
ViiV Healthcare
INDUSTRY
National Institute of Allergy and Infectious Diseases (NIAID)
NIH